Delcath Systems to Present at Rodman & Renshaw 11th Annual Healthcare Conference
04 September 2009 - 12:30PM
PR Newswire (US)
NEW YORK, Sept. 4 /PRNewswire-FirstCall/ -- Delcath Systems, Inc.
(NASDAQ: DCTH), a medical device company testing its proprietary
treatment method for primary and metastatic cancers to the liver,
announced that its President and CEO Eamonn P. Hobbs will make a
presentation to investors at the Rodman & Renshaw 11th Annual
Healthcare Conference on Friday, September 11 at 9:10 a.m. Eastern
Time in New York. Mr. Hobbs will review the Company's business
strategy and historic financial results. A live webcast of the
presentation will be available in the investors section of the
Company's web site at http://www.delcath.com/. The webcast also
will be archived and accessible for ninety days. Delcath Systems,
Inc. Delcath Systems, Inc. is a medical device company specializing
in cancer treatment. The Company is testing a proprietary, patented
drug delivery system for the delivery of ultra-high doses of
anti-cancer drugs to the liver while preventing these high doses of
drug from entering the patient's bloodstream. The Company is
currently enrolling patients in Phase III and Phase II clinical
studies for the treatment of liver cancers using high doses of
melphalan. The Company's intellectual property portfolio consists
of twenty-seven patents on a worldwide basis including the U.S.,
Europe, Asia and Canada. For more information, please visit the
Company's website at http://www.delcath.com/. DATASOURCE: Delcath
Systems, Inc. CONTACT: Investors, Doug Sherk, Stacey Fisher, or
Mike Pollack, +1-415-896-6820, or Media, Steve DiMattia,
+1-646-201-5445, all of EVC Group, for Delcath Systems, Inc. Web
Site: http://www.delcath.com/
Copyright